Combination pill and targeted therapy for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two medications, fruquintinib (a targeted drug that stops blood vessel growth) and a chemotherapy pill called tegafur/gimeracil/oteracil (often used after standard chemo has stopped helping). The goal is to see if this combination can help control advanced colorectal cancer that has not responded to at least two prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your colorectal cancer has spread to distant parts of the body (metastatic) and has been confirmed by a biopsy or cytology.
- You have already tried at least two standard chemotherapy treatments (including 5-FU/capecitabine, oxaliplatin, and irinotecan) and they did not work.
- You have at least one tumor that can be measured on a CT scan (larger than 10 mm by spiral CT or 20 mm by conventional CT).
- You are in generally good physical condition (able to do light activity and take care of yourself), with a life expectancy of at least 12 weeks.
- You have adequate liver, kidney, heart, and blood counts, and no serious medical issues like uncontrolled high blood pressure, bleeding problems, recent blood clots, or brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different drug combinations for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if one combination works as well as the other, potentially offering a new option.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
This trial tests a new combination of drugs for people with advanced colorectal cancer that has not responded to standard treatments. The drugs may help your immune system fight the cancer and block its growth.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This trial is testing a new combination of two oral cancer drugs (fruquintinib and S-1) in people with metastatic colorectal cancer who have already had at least one prior chemotherapy. The goal is to see if this combination helps shrink or slow the growth of tumors.
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.